Ratings for Hims & Hers Health HIMS were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 5 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 2 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 2 | 0 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.11, with a high estimate of $26.00 and a low estimate of $18.00. Observing a 31.53% increase, the current average has risen from the previous average price target of $16.81.
Decoding Analyst Ratings: A Detailed Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive Hims & Hers Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Korinne Wolfmeyer | Piper Sandler | Maintains | Neutral | $18.00 | $18.00 |
| Jailendra Singh | Truist Securities | Raises | Hold | $23.00 | $13.00 |
| Jonna Kim | TD Cowen | Raises | Buy | $25.00 | $15.00 |
| Korinne Wolfmeyer | Piper Sandler | Raises | Neutral | $18.00 | $16.00 |
| Glen Santangelo | Jefferies | Raises | Hold | $23.00 | $14.00 |
| Michael Cherny | B of A Securities | Raises | Buy | $26.00 | $22.00 |
| Michael Cherny | B of A Securities | Raises | Buy | $22.00 | $17.25 |
| Maria Ripps | Canaccord Genuity | Raises | Buy | $24.00 | $20.00 |
| Daniel Grosslight | Citigroup | Raises | Neutral | $20.00 | $16.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Hims & Hers Health. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Hims & Hers Health compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Hims & Hers Health's stock. This analysis reveals shifts in analysts' expectations over time.
Capture valuable insights into Hims & Hers Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Hims & Hers Health analyst ratings.
Get to Know Hims & Hers Health Better
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Unraveling the Financial Story of Hims & Hers Health
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Hims & Hers Health's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 45.81%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.0%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Hims & Hers Health's ROE excels beyond industry benchmarks, reaching 3.23%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Hims & Hers Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.5% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Hims & Hers Health adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
